
Evommune, Inc.: financial statements
Price
$7.04
November 20, 2026Market cap $291M
What Ploutos Investor adds for Evommune
Part of Ploutos Investor, €9.99 a month
- The full history: 2 fiscal years, from 2024
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Financial statements
Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.
Click a line to see it on the chart.
Revenue
| Line | 2024 | 2025 | Average a year |
|---|---|---|---|
| Revenue | $7.0M | $13M | |
| Operating income | -$70M | -$81M | |
| Net income | -$67M | -$69M | |
| Earnings per share | -$45.29 | -$11.22 | |
| Earnings per share, basic | -$45.29 | -$11.22 | |
| Margins | |||
| Operating margin | -1,000.2% | -623.6% | |
| Net margin | -954.4% | -529.8% | |
Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.
Debt and obligations
What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.
Leases
Dec 31, 2025Operating leases
$1.5M
Finance leases
$528.0K
- Average discount rate
- 8.3%
- Lease cost for the year
- $817.0K
The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing
Operating lease payments by year
From the statutory to the effective tax rate, 2025
Dec 31, 2025Statutory rate
21.0%
Effective rate
0.0%
The company paid 0.0% in tax on its profit, 21.0 points below the US federal rate (21.0%). Below, the reasons it gives.
Statutory rate
21.0%
Tax credits
+3.3 pts
Change in valuation allowance
-19.3 pts
Fair-value remeasurements
-2.7 pts
Share-based compensation
-1.2 pts
Uncertain tax positions
-0.7 pts
Non-deductible expenses
-0.4 pts
Effective rate
0.0%
One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing
Effective tax rate by year
Claims ahead of shareholders
What stands between the business and its shareholders besides the debt, and the financial assets on the other side, from the latest balance sheet.
Besides its debt, no other claim large enough to list ranks ahead of the shares.
On the other side, it holds $94M of long-term securities and stakes in other companies, at the value in its accounts, about 32% of the market value.
On the other side
- at Sep 30, 2026
- $94M
From the balance sheet of September 30, 2026. The retirement and environmental lines and the pension deficit come from the latest annual report when the quarter's filing does not state them, each with its own date. Market value at the price of November 20, 2026. A line is listed when it is at least 0.5% of the market value. A description of the balance sheet, not a valuation.
The metrics a company reports about itself (users, stores, subscribers) are read for S&P 500 companies only.
The full analysis
What do Evommune's filings show?
These are Evommune's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
How much revenue did EVMN have in 2025?
Evommune had revenue of $13M and net income of -$69M in fiscal 2025, a net margin of -529.8%.
How much debt does EVMN have?
On December 31, 2025 Evommune had total assets of $225M, debt of – and shareholders' equity of $206M.
How much free cash flow does EVMN have?
In fiscal 2025 Evommune had cash from operations of -$76M and spent $235.0K on capital expenditure, leaving -$77M of free cash flow.
Where are the figures from?
From Evommune, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.